PIK3CA and neoplasm: Moreover, we show that aminooxyacetate (AOA), a compound that inhibits enzymatic activity of aminotransferases, suppresses xenograft tumour growth of CRCs with PIK3CA mutations, but not with wild-type (WT) PIK3CA. These results suggest that reprogramming glutamine metabolism is crucial for the oncogenic function of PIK3CA mutations and that targeting glutamine metabolism may be an effective approach to treating CRC patients harbouring tumour mutations of this gene.